Get the Stockscreener App
11.58
2.93%
-0.35
Pre-market:
11.35
-0.23
-1.99%
Generate Biomedicines Inc stock is traded at $11.58, with a volume of 1.10M.
It is down -2.93% in the last 24 hours and up +0.00% over the past month.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
See More
Previous Close:
$11.93
Open:
$12.4
24h Volume:
1.10M
Relative Volume:
19.61
Market Cap:
$1.48B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$11.00
$12.40
1-Week Range:
$11.00
$13.95
52-Week Range:
$11.00
$13.95
Generate Biomedicines Inc Stock (GENB) Company Profile
Name
Generate Biomedicines Inc
Sector
Industry
Phone
-
Address
-
Compare GENB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GENB
Generate Biomedicines Inc
|
11.58 | 1.52B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Generate Biomedicines Inc Stock (GENB) Latest News
GENB PE Ratio & Valuation, Is GENB Overvalued - Intellectia AI
GENB | Generate Biomedicines, Inc. Common Institutional Ownership - Quiver Quantitative
GENB | Generate Biomedicines, Inc. Common Insider Trading - Quiver Quantitative
Insider Buying: Jane Mendillo Acquires Shares in Generate Biomed - GuruFocus
GENB: Static price chart | Generate Biomedicines, Inc. | US3709201004 - marketscreener.com
Assessing Generate Biomedicines (GENB) Valuation After Recent Share Price Volatility - simplywall.st
Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Generate Biomedicines amends charter and bylaws ahead of Nasdaq IPO By Investing.com - Investing.com UK
Generate Biomedicines amends charter and bylaws ahead of Nasdaq IPO - Investing.com
Generate Biomedicines, Inc.Common Stock (Nasdaq:GENB) Stock Quote - FinancialContent
Generate IPO raises $400 million but shares sink - The Pharma Letter
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to NASDAQ Composite Index - marketscreener.com
EBITDA of GENERATE BIOMEDICINES INC – NASDAQ:GENB - TradingView
Generate Biomedicines shares fall in weak Nasdaq debut for drug developer - WSAU
Generate Biomedicines prices IPO at $16 per share By Investing.com - Investing.com Australia
Generate Biomedicines Shares Plummet After $400 Million Market Debut - WSJ
U.S. IPO Weekly Recap: Asthma-Focused Generate Biomedicines Closes Out February IPO Market - Seeking Alpha
AI-Focused Generate Biomedicines Prices $400M IPO - Law360
Generate Biomedicines, AI-Driven Generative Biology Drug Developer, Files for Nasdaq Global Select Market IPO - TradingView
Generate Biomedicines Share Price Target and Forecast - Investing.com India
Generate Biomedicines’ IPO Brings In $400M for Pivotal Tests of Severe Asthma Drug - MedCity News
Generate Biomedicines stock opens below IPO price in Nasdaq debut By Investing.com - Investing.com South Africa
Generate Biomedicines stock opens below IPO price in Nasdaq debut - Investing.com Nigeria
Generate Biomedicines Shares Fall After Nasdaq Debut - marketscreener.com
Generate Biomedicines shares fall 6% in weak Nasdaq debut for drug developer - TradingView
Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut - marketscreener.com
Shares of Generate Biomedicines open at $15 in their Nasdaq debut vs $16 IPO price - marketscreener.com
Generate Biomedicines, Inc. share price - Capital.com
AI-driven drug developer nets $400M IPO, matching 2020 record - The Business Journals
Generate’s $400m IPO Adds To Biotech Bounceback - Citeline News & Insights
Rx Rundown: Gilead Sciences, Viatris, Generate Biomedicines and moreMM+MMedical Marketing and Media - Medical Marketing and Media
Trade Generate Biomedicines, Inc.GENB CFD - Capital.com
Generate:Biomedicines Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Generate:Biomedicines Rings the Opening Bell - Nasdaq
Generate Biomedicines secures $400m IPO in flurry of February listings - Yahoo Finance
Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering - The Malaysian Reserve
Generate Biomedicines Announces IPO Terms for $400 Million Raise - Intellectia AI
GENB Stock Price, News & Analysis - Stock Titan
Drug developer Generate Biomedicines raises $400 million in US IPO - marketscreener.com
Generate caps a strong month for biotech IPOs with $400M offering - BioPharma Dive
AI biotech Generate Biomedicines raises $400M in IPO - Axios
Generate Biomedicines prices IPO at $16 per share - Investing.com
Lo sviluppatore di farmaci Generate Biomedicines raccoglie 400 milioni di dollari nell'IPO statunitense - TradingView
Flagship-Backed Generate Biomedicines Raises $400 Million in IPO - Bloomberg.com
GENBGenerate Biomedicines Latest Stock News & Market Updates - Stock Titan
Flagship-backed Generate Bio seeks $425 million in US IPO - MSN
Generate Biomedicines (GENB) Stock Forecast & Price Target - Investing.com
Generate Biomedicines IPO Closing Market Cap Trading Odds & Predictions - Polymarket
Generate Biomedicines Inc Consensus Estimates (GENB) - Investing.com South Africa
AI pharmaceutical company Generate Biomedicines (GENB.US) sets IPO price at $16 per share, to be listed on Nasdaq tonight - Bitget
Preview: Generate Biomedicines, Inc Set To IPO Tomorrow - Benzinga
Generate Biomedicines Inc Stock (GENB) Financials Data
There is no financial data for Generate Biomedicines Inc (GENB). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):